{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:41:28Z","timestamp":1794850888763,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda Pharmaceutical Company Limited","award":["Takeda Pharmaceutical Company Limited"],"award-info":[{"award-number":["Takeda Pharmaceutical Company Limited"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gaucher disease (GD) is an autosomal recessive disease caused by <jats:italic>GBA1<\/jats:italic> mutations resulting in glucosylceramide accumulation in macrophages. GD is characterized by hepatosplenomegaly, anemia, thrombocytopenia, bone complications, and neurological complications. Glucosylsphingosine (lyso-Gb1), a deacylated form of glucosylceramide, has been identified as a promising biomarker for the diagnosis and treatment response in GD. The aim of this study was to examine the relationship between plasma lyso-Gb1 and therapeutic goals for GD (improvements in hepatomegaly, splenomegaly, anemia, thrombocytopenia, bone pain, and bone crisis), as well as disease type and <jats:italic>GBA1<\/jats:italic> mutation type, in Japanese patients with GD receiving velaglucerase alfa, an enzyme replacement therapy (ERT). Furthermore, this study compared the plasma lyso-Gb1 concentration observed in Japanese patients included in this study with that observed in a previous non-Japanese clinical study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This non-interventional, open-label, multicenter observational cohort study (October 2020 to March 2021) included a total of 20 patients (of any age) with GD (type 1: n\u2009=\u20098; type 2: n\u2009=\u20099; type 3: n\u2009=\u20093) treated with velaglucerase alfa for\u2009\u2265\u20093\u00a0months. Median (minimum\u2013maximum) duration of velaglucerase alfa treatment was 49.5 (3\u2013107) months. A total of 14 (70.0%) patients achieved all therapeutic goals (i.e., 100% achievement; improvements in hepatomegaly, splenomegaly, anemia, thrombocytopenia, bone pain, and bone crisis). Overall, median (minimum\u2013maximum) lyso-Gb1 concentration was 24.3 (2.1\u2013150) ng\/mL. Although not statistically significant, numerically lower plasma lyso-Gb1 concentrations were observed in patients with 100% achievement compared with those without; no statistically significant difference in plasma lyso-Gb1 concentration was observed between patients with different disease type or mutation type. Furthermore, lyso-Gb1 concentrations observed in Japanese patients were numerically lower than that observed in a previous study of non-Japanese patients with GD receiving ERT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this study, high achievement rates of therapeutic goals with low lyso-Gb1 concentration were observed, demonstrating a correlation between therapeutic goals and lower plasma lyso-Gb1 concentration in Japanese patients with GD treated with velaglucerase alfa. This study further suggests that plasma lyso-Gb1 concentration may be a useful biomarker for treatment response in patients with GD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02549-6","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T15:04:37Z","timestamp":1667487877000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["An observational study to investigate the relationship between plasma glucosylsphingosine (lyso-Gb1) concentration and treatment outcomes of patients with Gaucher disease in Japan"],"prefix":"10.1186","volume":"17","author":[{"given":"Hiroyuki","family":"Ida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2735-6985","authenticated-orcid":false,"given":"Yuko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieko","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovelle","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"2549_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/10245332.2016.1240391","volume":"22","author":"L Nalysnyk","year":"2017","unstructured":"Nalysnyk L, Rotella P, Simeone JC, Hamed A, Weinreb N. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology. 2017;22:65\u201373.","journal-title":"Hematology"},{"key":"2549_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ijms18020441","volume":"18","author":"J Stirnemann","year":"2017","unstructured":"Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18:441.","journal-title":"Int J Mol Sci"},{"key":"2549_CR3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/ajh.24491","volume":"91","author":"V Murugesan","year":"2016","unstructured":"Murugesan V, Chuang W-L, Liu J, Lischuk A, Kacena K, Lin H, et al. Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol. 2016;91:1082\u20139.","journal-title":"Am J Hematol"},{"key":"2549_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000440865","volume":"83","author":"A Dandana","year":"2016","unstructured":"Dandana A, Ben Khelifa S, Chahed H, Miled A, Ferchichi S. Gaucher disease: clinical, biological and therapeutic aspects. Pathobiology. 2016;83:13\u201323.","journal-title":"Pathobiology"},{"key":"2549_CR5","unstructured":"Japanese Society of Inherited Metabolic Disease. Practical guideline for the management of Gaucher diseases 2021 [Japanese]. Tokyo: Shindan To Chiryo Sha; 2021."},{"key":"2549_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ymgme.2021.05.004","volume":"133","author":"Y Koto","year":"2021","unstructured":"Koto Y, Sakai N, Lee Y, Kakee N, Matsuda J, Tsuboi K, et al. Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: a nationwide survey in Japan. Mol Genet Metab. 2021;133:277\u201388.","journal-title":"Mol Genet Metab"},{"key":"2549_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1023\/A:1005313724361","volume":"20","author":"H Ida","year":"1997","unstructured":"Ida H, Rennert OM, Kawame H, Maekawa K, Eto Y. Mutation prevalence among 47 unrelated Japanese patients with Gaucher disease: identification of four novel mutations. J Inherit Metab Dis. 1997;20:67\u201373.","journal-title":"J Inherit Metab Dis"},{"key":"2549_CR8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/BF00209497","volume":"95","author":"H Ida","year":"1995","unstructured":"Ida H, Iwasawa K, Kawame H, Rennert OM, Maekawa K, Eto Y. Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations. Hum Genet. 1995;95:717\u201320.","journal-title":"Hum Genet"},{"key":"2549_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ymgme.2009.05.001","volume":"97","author":"A Tajima","year":"2009","unstructured":"Tajima A, Yokoi T, Ariga M, Ito T, Kaneshiro E, Eto Y, et al. Clinical and genetic study of Japanese patients with type 3 Gaucher disease. Mol Genet Metab. 2009;97:272\u20137.","journal-title":"Mol Genet Metab"},{"key":"2549_CR10","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","volume":"160","author":"J Charrow","year":"2000","unstructured":"Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. The Gaucher Registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000;160:2835\u201343.","journal-title":"Arch Intern Med"},{"key":"2549_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ymgme.2018.02.007","volume":"123","author":"SM Danilov","year":"2018","unstructured":"Danilov SM, Tikhomirova VE, Metzger R, Naperova IA, Bukina TM, Goker-Alpan O, et al. ACE phenotyping in Gaucher disease. Mol Genet Metab. 2018;123:501\u201310.","journal-title":"Mol Genet Metab"},{"key":"2549_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/08035320510028094","volume":"94","author":"JM Aerts","year":"2005","unstructured":"Aerts JM, Hollak CE, van Breemen M, Maas M, Groener JE, Boot RG. Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases. Acta Paediatr Suppl. 2005;94:43\u20136.","journal-title":"Acta Paediatr Suppl"},{"key":"2549_CR13","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1172\/JCI117084","volume":"93","author":"CE Hollak","year":"1994","unstructured":"Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 1994;93:1288\u201392.","journal-title":"J Clin Invest"},{"key":"2549_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","volume":"103","author":"RG Boot","year":"2004","unstructured":"Boot RG, Verhoek M, de Fost M, Hollak CE, Maas M, Bleijlevens B, et al. Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood. 2004;103:33\u20139.","journal-title":"Blood"},{"key":"2549_CR15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/ajh.24399","volume":"91","author":"GM Pastores","year":"2016","unstructured":"Pastores GM, Shankar SP, Petakov M, Giraldo P, Rosenbaum H, Amato DJ, et al. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase. Am J Hematol. 2016;91:661\u20135.","journal-title":"Am J Hematol"},{"key":"2549_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ajh.23381","volume":"88","author":"DE Gonzalez","year":"2013","unstructured":"Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MF, Elstein D, et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, Phase 3 study. Am J Hematol. 2013;88:166\u201371.","journal-title":"Am J Hematol"},{"key":"2549_CR17","doi-asserted-by":"publisher","first-page":"25680","DOI":"10.1074\/jbc.273.40.25680","volume":"273","author":"RG Boot","year":"1998","unstructured":"Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, de Meulemeester TM, et al. The human chitotriosidase gene: nature of inherited enzyme deficiency. J Biol Chem. 1998;273:25680\u20135.","journal-title":"J Biol Chem"},{"key":"2549_CR18","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.3390\/ijms18102192","volume":"18","author":"J Lukas","year":"2017","unstructured":"Lukas J, Cozma C, Yang F, Kramp G, Meyer A, Ne\u00dflauer AM, et al. Glucosylsphingosine causes hematological and visceral changes in mice\u2014evidence for a pathophysiological role in Gaucher disease. Int J Mol Sci. 2017;18:2192.","journal-title":"Int J Mol Sci"},{"key":"2549_CR19","doi-asserted-by":"publisher","first-page":"e79732","DOI":"10.1371\/journal.pone.0079732","volume":"8","author":"A Rolfs","year":"2013","unstructured":"Rolfs A, Giese A-K, Grittner U, Mascher D, Elstein D, Zimran A, et al. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS One. 2013;8:e79732.","journal-title":"PLoS One"},{"key":"2549_CR20","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","volume":"118","author":"N Dekker","year":"2011","unstructured":"Dekker N, van Dussen L, Hollak CEM, Overkleeft H, Scheij S, Ghauharali K, et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011;118:e118\u201327.","journal-title":"Blood"},{"key":"2549_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ymgme.2017.08.005","volume":"122","author":"D Elstein","year":"2017","unstructured":"Elstein D, Mellgard B, Dinh Q, Lan L, Qiu Y, Cozma C, et al. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-na\u00efve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: data from phase 3 clinical trials. Mol Genet Metab. 2017;122:113\u201320.","journal-title":"Mol Genet Metab"},{"key":"2549_CR22","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.3390\/ijms20123033","volume":"20","author":"N Hurvitz","year":"2019","unstructured":"Hurvitz N, Dinur T, Becker-Cohen M, Cozma C, Hovakimyan M, Oppermann S, et al. Glucosylsphingosine (lyso-Gb1) as a biomarker for monitoring treated and untreated children with Gaucher disease. Int J Mol Sci. 2019;20:3033.","journal-title":"Int J Mol Sci"},{"key":"2549_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-016-0413-3","volume":"11","author":"BE Smid","year":"2016","unstructured":"Smid BE, Ferraz MJ, Verhoek M, Mirzaian M, Wisse P, Overkleeft HS, et al. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients. Orphanet J Rare Dis. 2016;11:28.","journal-title":"Orphanet J Rare Dis"},{"key":"2549_CR24","doi-asserted-by":"publisher","first-page":"E140","DOI":"10.1002\/ajh.25074","volume":"93","author":"D Arkadir","year":"2018","unstructured":"Arkadir D, Dinur T, Revel-Vilk S, Becker Cohen M, Cozma C, Hovakimyan M, et al. Glucosylsphingosine is a reliable response biomarker in Gaucher disease. Am J Hematol. 2018;93:E140\u20132.","journal-title":"Am J Hematol"},{"key":"2549_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1023\/A:1022553819241","volume":"24","author":"Y Eto","year":"1999","unstructured":"Eto Y, Ida H. Clinical and molecular characteristics of Japanese Gaucher disease. Neurochem Res. 1999;24:207\u201311.","journal-title":"Neurochem Res"},{"key":"2549_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/GIM.0b013e318211a7e1","volume":"13","author":"RY Wang","year":"2011","unstructured":"Wang RY, Bodamer OA, Watson MS, Wilcox WR. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med. 2011;13:457\u201384.","journal-title":"Genet Med"},{"key":"2549_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1006\/bcmd.1998.0172","volume":"24","author":"H Ida","year":"1998","unstructured":"Ida H, Rennert OM, Ito T, Maekawa K, Eto Y. Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients. Blood Cells Mol Dis. 1998;24:73\u201381.","journal-title":"Blood Cells Mol Dis"},{"key":"2549_CR28","unstructured":"Pharmaceuticals and Medical Devices Agency. VPRIV Intravenous infusion 400 U [package insert]. Item in Japanese. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/400256_3959416F1020_3_01. Accessed 20 Dec 2021."},{"key":"2549_CR29","doi-asserted-by":"publisher","first-page":"100476","DOI":"10.1016\/j.ymgmr.2019.100476","volume":"20","author":"B Charkhand","year":"2019","unstructured":"Charkhand B, Scantlebury MH, Narita A, Zimran A, Al-Hertani W. Effect of ambroxol chaperone therapy on glucosylsphingosine (lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease. Mol Genet Metab Rep. 2019;20:100476.","journal-title":"Mol Genet Metab Rep"},{"key":"2549_CR30","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/ajh.21280","volume":"83","author":"N Weinreb","year":"2008","unstructured":"Weinreb N, Taylor J, Cox T, Yee J, vom Dahl S. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am J Hematol. 2008;83:890\u20135.","journal-title":"Am J Hematol"},{"key":"2549_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0140-6736(89)90536-9","volume":"334","author":"A Zimran","year":"1989","unstructured":"Zimran A, Gross E, West C, Sorge J, Kubitz M, Beutler E. Prediction of severity of Gaucher\u2019s disease by identification of mutations at DNA level. Lancet. 1989;334:349\u201352.","journal-title":"Lancet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02549-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02549-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02549-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T15:07:26Z","timestamp":1667488046000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02549-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2549"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02549-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]},"assertion":[{"value":"25 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, Good Pharmacoepidemiology Practices, and local laws and regulations. All patients provided written informed consent before entering the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HI received research funding from Sanofi K.K. and Sumitomo Dainippon Pharma Co. Ltd., and consultancy fees from JCR Pharmaceuticals Co., Ltd. and Takeda Pharmaceutical Company Limited. YW, RS, and YI are employees of Takeda Pharmaceutical Company Limited. JF is a former employee of Takeda Pharmaceutical Company Limited, and owns restricted stocks of Takeda Pharmaceutical Company Limited and GlaxoSmithKline K.K.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"401"}}